PT839525E - Preparacao de libertacao prolongada - Google Patents

Preparacao de libertacao prolongada

Info

Publication number
PT839525E
PT839525E PT97308692T PT97308692T PT839525E PT 839525 E PT839525 E PT 839525E PT 97308692 T PT97308692 T PT 97308692T PT 97308692 T PT97308692 T PT 97308692T PT 839525 E PT839525 E PT 839525E
Authority
PT
Portugal
Prior art keywords
preparation
active substance
physiologically active
sustained
months
Prior art date
Application number
PT97308692T
Other languages
English (en)
Inventor
Hiroaki Okada
Yayoi Douken
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PT839525E publication Critical patent/PT839525E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
PT97308692T 1996-10-31 1997-10-30 Preparacao de libertacao prolongada PT839525E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP29044196 1996-10-31

Publications (1)

Publication Number Publication Date
PT839525E true PT839525E (pt) 2004-10-29

Family

ID=17756079

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97308692T PT839525E (pt) 1996-10-31 1997-10-30 Preparacao de libertacao prolongada

Country Status (9)

Country Link
US (2) US6113943A (pt)
EP (1) EP0839525B1 (pt)
JP (1) JP4361144B2 (pt)
AT (1) ATE272394T1 (pt)
CA (1) CA2219698C (pt)
DE (1) DE69730093T2 (pt)
DK (1) DK0839525T3 (pt)
ES (1) ES2221019T3 (pt)
PT (1) PT839525E (pt)

Families Citing this family (337)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
EP0998940A1 (en) * 1998-09-30 2000-05-10 Laboratoire Theramex Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues
CA2355186C (en) 1998-12-15 2008-03-18 Takeda Chemical Industries, Ltd. Process for producing polymer
WO2000054797A2 (en) 1999-03-17 2000-09-21 Novartis Ag Pharmaceutical compositions comprising tgf-beta
NZ516466A (en) 1999-07-15 2003-02-28 Takeda Chemical Industries Ltd Sustained release compositions, process for producing the same and use thereof
US6303138B1 (en) 1999-09-17 2001-10-16 Depuy Orthopaedics Endothelin-based compositions for enhancing connective tissue repair
ES2253375T3 (es) 2000-04-19 2006-06-01 Genentech, Inc. Formulaciones de liberacion sostenida.
JP2003531682A (ja) * 2000-04-28 2003-10-28 フジオメッド インコーポレイテッド ポリ酸及びポリアルキレンオキシドの止血性組成物、並びにその使用方法
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
JP2002003406A (ja) * 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
EP1310517B2 (en) * 2000-08-07 2010-11-17 Wako Pure Chemical Industries, Ltd. Lactic acid polymer and process for producing the same
AU2002232824A1 (en) 2000-12-21 2002-07-01 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents
GB0100761D0 (en) * 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
JP4724354B2 (ja) * 2001-02-23 2011-07-13 ジェネンテック， インコーポレイテッド 注射用の崩壊性ポリマー
US6558702B2 (en) * 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
EP1382350A4 (en) * 2001-04-25 2006-01-04 Takeda Pharmaceutical MEANS AGAINST THE PROPHYLAXIS BEFORE POSTOPERATIVE REPEAT OF PREMOPEOPAUSAL BREAST CANCER
CA2448218C (en) * 2001-06-21 2012-05-29 Genentech, Inc. Sustained release formulation
AR034641A1 (es) 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
US8535650B2 (en) * 2001-12-03 2013-09-17 Soligenix, Inc. Stabilized reverse micelle compositions and uses thereof
JP2003192773A (ja) * 2001-12-26 2003-07-09 Mitsui Chemicals Inc 生体吸収性ポリヒドロキシカルボン酸及びその製造法
EP1488807A4 (en) * 2002-03-11 2009-07-08 Takeda Pharmaceutical MEDICAMENTS FOR TREATING SEXUAL HORMONE DEPENDENT DISEASE
KR101041767B1 (ko) * 2002-06-25 2011-06-17 다케다 야쿠힌 고교 가부시키가이샤 서방성 조성물의 제조 방법
JP2007525429A (ja) * 2003-03-11 2007-09-06 キューエルティー ユーエスエー，インコーポレイテッド． 細胞スケジュール依存性抗癌剤のための処方
CA2523859C (en) * 2003-04-29 2011-08-02 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
US20040244806A1 (en) * 2003-06-09 2004-12-09 Ferree Bret A. Treating disc herniation and other conditions with leukocytes
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
PL196544B1 (pl) 2003-08-08 2008-01-31 Biovail Lab Int Srl Tabletka o zmodyfikowanym uwalnianiu
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
US8846069B2 (en) 2003-11-20 2014-09-30 Abbott Cardiovascular Systems Inc. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
US20050112170A1 (en) * 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20060094651A1 (en) * 2004-11-03 2006-05-04 Cyrus Karkaria Formulations and methods of production of FGF-20
CA2569513C (en) 2004-06-04 2013-08-06 Camurus Ab Preformulation for liquid crystalline phase structure
WO2005122734A2 (en) * 2004-06-14 2005-12-29 The Research Foundation Of State University Of New York Nanosphere/microsphere delivery system for the treatment of spinal cord injury
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
US20060039890A1 (en) * 2004-08-20 2006-02-23 Renshaw Perry F Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
KR20070083941A (ko) * 2004-10-04 2007-08-24 큐엘티 유에스에이, 인코포레이티드 중합체 전달 조성을 갖는 눈 전달
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
ATE462409T1 (de) 2005-01-14 2010-04-15 Camurus Ab Topische bioadhäsive formulierungen
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
DE602005026998D1 (de) * 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
CA2595385C (en) 2005-01-21 2011-01-25 Camurus Ab Pharmaceutical lipid compositions
US8222257B2 (en) 2005-04-01 2012-07-17 The Regents Of The University Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
DE602006000381T2 (de) 2005-04-28 2008-12-18 Nipro Corp., Osaka Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer
EP1888031B1 (en) * 2005-06-06 2013-01-23 Camurus Ab Glp-1 analogue formulations
JPWO2007029361A1 (ja) * 2005-09-02 2009-03-12 武田薬品工業株式会社 短鎖デオキシリボ核酸又は短鎖リボ核酸含有徐放性マイクロスフェア及びその製造法
PT1787658E (pt) 2005-11-10 2012-06-22 Chemi Spa Formulações de libertação sustentada de análogos de somatostatina inibidores da hormona do crescimento
EP3363455A1 (en) 2005-12-30 2018-08-22 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
RU2008136315A (ru) * 2006-03-13 2010-04-20 Инсайсив Фармасьютикалз, Инк. (US) Композиции ситаксентана натрия
WO2007106494A2 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of diastolic heart failure
KR101419554B1 (ko) 2006-03-13 2014-07-17 교린 세이야꾸 가부시키 가이샤 Ｇｓｋ­３ 억제제로서 아미노퀴놀론
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
PT2066662E (pt) 2006-09-21 2013-02-13 Kyorin Seiyaku Kk Inibidores de serina-hidrolase
CA2666149A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US20100137421A1 (en) * 2006-11-08 2010-06-03 Emmanuel Theodorakis Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
US7713541B1 (en) 2006-11-21 2010-05-11 Abbott Cardiovascular Systems Inc. Zwitterionic terpolymers, method of making and use on medical devices
EP2094246B1 (en) 2006-12-18 2020-04-01 Takeda Pharmaceutical Company Limited Sustained-release composition and method for producing the same
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
KR20090086115A (ko) * 2006-12-22 2009-08-10 엔싸이시브 파마슈티칼즈 인코퍼레이티드 Ｃ３ａ 수용체의 조정제 및 이의 사용 방법
ATE525068T1 (de) * 2007-02-28 2011-10-15 Conatus Pharmaceuticals Inc Verfahren zur behandlung von chronischer viraler hepatitis c mithilfe von ro 113-0830
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
HUE031070T2 (en) 2007-03-15 2017-06-28 Auspex Pharmaceuticals Inc Deuterated d9-venlafaxine
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
EA201000016A1 (ru) * 2007-07-12 2010-10-29 Трагара Фармасьютикалс, Инк. Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
BRPI0816798A2 (pt) * 2007-09-11 2016-10-11 Activx Biosciences Inc composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
EP2203459B1 (en) 2007-09-12 2016-03-16 Kyorin Pharmaceutical Co., Ltd. Spirocyclic aminoquinolones as gsk-3 inhibitors
ES2528409T3 (es) 2007-10-24 2015-02-10 Camurus Ab Formulaciones de liberación controlada
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
PL2947072T3 (pl) 2008-03-17 2017-05-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
WO2009139880A1 (en) * 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
MX2010012514A (es) * 2008-05-20 2011-05-30 Cerenis Therapeutics S A Niacina y un medicamento nsaid para tratamiento combinado.
AU2009277172B2 (en) 2008-07-02 2014-05-29 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
US20100152227A1 (en) * 2008-12-11 2010-06-17 A.P. Pharma, Inc. Methods for Enhancing Stability of Polyorthoesters and Their Formulations
WO2010076329A1 (en) 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
EP2601934A1 (en) 2009-01-22 2013-06-12 Ludwig-Maximilians-Universität München Vesicular phospholipid gels comprising proteinaceous substances
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
NZ594661A (en) 2009-02-27 2013-11-29 Ambit Biosciences Corp Jak kinase modulating quinazoline derivatives and methods of use thereof
EP2403860B1 (en) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
BRPI1008974A2 (pt) * 2009-03-11 2017-06-06 Kyorin Seiyaku Kk composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
EP2411387B1 (en) 2009-03-27 2015-08-19 VetDC, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CN102459177B (zh) 2009-04-22 2015-09-02 埃克希金医药品有限公司 2,5-二取代的芳基磺酰胺ccr3拮抗剂
HUE025647T2 (en) 2009-04-22 2016-04-28 Axikin Pharmaceuticals Inc Arylsulfonamide CCR3 antagonists
MX2011011139A (es) 2009-04-22 2012-01-27 Axikin Pharmaceuticals Inc Antagonistas ccr3 arisulfonamida 2, 5-disustituidos.
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
EP2451802A1 (en) 2009-07-07 2012-05-16 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
HUE035519T2 (en) 2009-07-08 2018-05-02 Hope Medical Entpr Inc D B A Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical composition
US20110020272A1 (en) 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
CN102470127A (zh) 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
US20110301235A1 (en) 2009-12-02 2011-12-08 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
US8362068B2 (en) 2009-12-18 2013-01-29 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
EP2515654A4 (en) * 2009-12-23 2013-04-24 Map Pharmaceuticals Inc NEW ERGOLINANALOGA
WO2011082289A1 (en) 2009-12-30 2011-07-07 Scynexis Inc. Cyclosporine analogues
WO2011089167A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
EP2531197B1 (en) 2010-02-05 2017-05-17 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
PL3202461T3 (pl) 2010-02-11 2019-07-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
US8999995B2 (en) 2010-03-02 2015-04-07 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
AR080770A1 (es) 2010-03-17 2012-05-09 Axikin Pharmaceuticals Inc Piperidinsulfonamidas moduladoras de la actividad de receptores xcc3, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de patologias respiratorias,tales como asma, entre otras.
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
US9296722B2 (en) 2010-05-27 2016-03-29 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
JP6019015B2 (ja) 2010-06-01 2016-11-02 ビオトヘルイク， インコーポレイテッド ６−シクロヘキシル−１−ヒドロキシ−４−メチル−２（１ｈ）−ピリドンを使用する血液悪性疾患の治療方法
CN104945318A (zh) 2010-06-01 2015-09-30 拜欧赛里克斯公司 羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
CA2801778C (en) 2010-06-07 2018-06-05 Novomedix, Llc Furanyl compounds and the use thereof
CA2805745C (en) 2010-07-19 2019-01-15 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
US8633207B2 (en) 2010-09-01 2014-01-21 Ambit Biosciences Corporation Quinazoline compounds and methods of use thereof
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
JP5932794B2 (ja) 2010-09-01 2016-06-08 アムビト ビオスシエンセス コルポラチオン 光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法
WO2012030885A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Hydrobromide salts of a pyrazolylaminoquinazoline
WO2012030912A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
EP2611794A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
EP2611809A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012030894A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2012051090A1 (en) 2010-10-11 2012-04-19 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US20140079686A1 (en) 2010-12-06 2014-03-20 Shikha P. Barman Methods For Treating Baldness And Promoting Hair Growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
TWI546305B (zh) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
CA2825152A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
WO2012106634A1 (en) 2011-02-03 2012-08-09 Alexion Pharmaceuticals, Inc. Use of an anti-cd200 antibody for prolonging the survival of allografts
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
DK2683384T3 (da) 2011-03-11 2016-02-08 Celgene Corp Fremgangsmåder til behandling af cancer under anvendelse af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion
US20140088103A1 (en) 2011-03-28 2014-03-27 Mei Pharma, Inc. (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
BR112013024909A2 (pt) 2011-03-28 2019-09-24 Mei Pharma Inc composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
CN107501241B (zh) 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8604035B2 (en) 2011-06-23 2013-12-10 Map Pharmaceuticals, Inc. Fluoroergoline analogs
US9326951B2 (en) 2011-06-28 2016-05-03 Yale University Cell-free tissue engineered vascular grafts
CN103946226A (zh) 2011-07-19 2014-07-23 无限药品股份有限公司 杂环化合物及其应用
JP6027610B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
CA2847892A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
AR089568A1 (es) 2011-10-14 2014-09-03 Ambit Biosciences Corp Compuestos heterociclicos y sus metodos de usos
US8586527B2 (en) 2011-10-20 2013-11-19 Jaipal Singh Cerivastatin to treat pulmonary disorders
BR112014013693B1 (pt) 2011-12-05 2023-01-31 Camurus Ab Pré-formulação, e, uso de uma pré-formulação
WO2013095707A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
SG11201403433PA (en) 2011-12-21 2014-07-30 Map Pharmaceuticals Inc Novel neuromodulatory compounds
RS59734B1 (sr) 2012-01-23 2020-02-28 Sage Therapeutics Inc Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
SG11201405761WA (en) 2012-03-16 2014-10-30 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013177219A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. D-amino acid compounds for liver disease
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
US9109001B2 (en) 2012-05-22 2015-08-18 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphoramidate prodrugs for HCV infection
SG11201407678YA (en) 2012-05-25 2014-12-30 Camurus Ab Somatostatin receptor agonist formulations
CN110664816A (zh) 2012-06-07 2020-01-10 佐治亚州立大学研究基金会公司 Seca抑制剂以及其制备和使用方法
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
EP3326613A1 (en) 2012-07-26 2018-05-30 Camurus AB Opioid formulations
RS58548B1 (sr) 2012-08-09 2019-05-31 Celgene Corp Čvrsta forma (s)-3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-dion hidrohlorida
PL2882441T3 (pl) 2012-08-09 2020-09-21 Celgene Corporation Leczenie chorób immunologicznych i zapalnych
JP6355633B2 (ja) 2012-08-21 2018-07-11 セージ セラピューティクス， インコーポレイテッド てんかんまたはてんかん重積状態の処置方法
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
WO2014039748A1 (en) 2012-09-07 2014-03-13 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide ccr3 antagonists
RU2650646C2 (ru) 2012-09-27 2018-04-16 Дзе Чилдрен'З Медикал Сентер Корпорейшн Соединения, предназначенные для лечения ожирения, и способы их применения
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
AP2015008384A0 (en) 2012-10-08 2015-04-30 Univ Montpellier Ct Nat De La Rech Scient 2'-Chloro nucleoside analogs for hcv infection
WO2014063019A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20150272924A1 (en) 2012-11-08 2015-10-01 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
WO2014078427A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
MX370519B (es) 2012-11-30 2019-12-17 Novomedix Llc Sulfonamidas con sustitucion biarilo y su uso.
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
BR112015014964A2 (pt) 2012-12-21 2017-07-11 Map Pharmaceuticals Inc novos derivados de metisergida
EP2943188A1 (en) 2013-01-11 2015-11-18 Mayo Foundation for Medical Education and Research Vitamins c and k for treating polycystic diseases
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
US20140377258A1 (en) 2013-05-30 2014-12-25 Infinity Pharmaceuticals, Inc. Treatment Of Cancers Using PI3 Kinase Isoform Modulators
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
RU2016111675A (ru) 2013-08-30 2017-10-04 Эмбит Байосайенсиз Корпорейшн Соединения биарилацетамида и способы их применения
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ718430A (en) 2013-10-04 2021-12-24 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
TR201901299T4 (tr) 2013-11-26 2019-02-21 Childrens Medical Ct Corp Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri.
WO2015081297A1 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
US10030044B2 (en) 2013-11-27 2018-07-24 Idenix Pharmaceuticals Llc Nucleotides for the treatment of liver cancer
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
AU2015231215B2 (en) 2014-03-20 2019-07-18 Capella Therapeutics, Inc. Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer
DK3119762T3 (da) 2014-03-20 2021-08-30 Capella Therapeutics Inc Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CA2944549A1 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxin useful for the treatment of pain
US10202411B2 (en) 2014-04-16 2019-02-12 Idenix Pharmaceuticals Llc 3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
RU2016148364A (ru) 2014-05-12 2018-06-13 Конатус Фармасьютикалз, Инк. Лечение осложнений хронического заболевания печени
WO2015181624A2 (en) 2014-05-28 2015-12-03 Idenix Pharmaceuticals, Inc Nucleoside derivatives for the treatment of cancer
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
BR112016029662B1 (pt) 2014-06-19 2023-10-24 Takeda Pharmaceutical Company Limited COMPOSTO DE FÓRMULA Bf OU UMA FORMA FARMACEUTICAMENTE ACEITÁVEL DO MESMO, COMPOSIÇÃO FARMACÊUTICA COMPREENDENDO O MESMO E SEU USO
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
CA2960284A1 (en) 2014-09-12 2016-03-17 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA119794C2 (uk) 2014-10-21 2019-08-12 Аріад Фармасьютикалз, Інк. Кристалічна форма 5-хлор-n4-[2-(диметилфосфорил)феніл]-n2-{2-метокси-4-[4-(4-метилпіперазин-1-іл)піперидин-1-іл]}піримідин-2,4-діаміну
WO2016065264A1 (en) 2014-10-24 2016-04-28 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
MX2017008526A (es) 2014-12-23 2017-10-25 Axikin Pharmaceuticals Inc Inhibidores de 3,5-diaminopirazol quinasa.
JP2018502889A (ja) 2015-01-20 2018-02-01 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ イソエルゴリン化合物およびその使用
MX2017009405A (es) 2015-01-20 2018-01-18 Xoc Pharmaceuticals Inc Compuestos de tipo ergolina y usos de estos.
US10815264B2 (en) 2015-05-27 2020-10-27 Southern Research Institute Nucleotides for the treatment of cancer
CN107921032B (zh) 2015-06-23 2021-09-24 纽罗克里生物科学有限公司 用于治疗神经学疾病或病症的vmat2抑制剂
EA201890512A1 (ru) 2015-08-17 2018-09-28 Кура Онколоджи, Инк. Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
CN108473503A (zh) 2015-09-30 2018-08-31 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
CN115304596A (zh) 2015-10-30 2022-11-08 纽罗克里生物科学有限公司 Valbenazine盐及其多晶形物
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
RS63170B1 (sr) 2015-12-23 2022-05-31 Neurocrine Biosciences Inc Sintetički postupak za pripremanje (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1,-a]izohinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
SG11201805480TA (en) 2015-12-31 2018-07-30 Conatus Pharmaceuticals Inc Methods of using caspase inhibitors in treatment of liver disease
BR112018013761A2 (pt) 2016-01-08 2018-12-11 Celgene Corp compostos antiproliferativos e suas composições farmacêuticas e usos
JP6880037B2 (ja) 2016-01-08 2021-06-02 セルジーン コーポレイション がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
TWI733734B (zh) 2016-01-08 2021-07-21 美商西建公司 2-(4-氯苯基)-n-((2-(2,6-二氧六氫吡啶-3-基)-1-氧基異吲哚啉-5-基)甲基)-2,2-二氟乙醯胺之固體型式，及其醫藥組合物及用途
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
EP3442940A1 (en) 2016-04-11 2019-02-20 Clexio Biosciences Ltd. Deuterated ketamine derivatives
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
CN109476635B (zh) 2016-04-29 2021-07-13 Fgh生物科技公司 用于治疗疾病的二取代吡唑类化合物
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP7071981B2 (ja) 2016-09-07 2022-05-19 エフジーエイチ バイオテック，インコーポレーテッド 疾患の治療のための二置換ピラゾール化合物
MA46285A (fr) 2016-09-19 2019-07-31 Mei Pharma Inc Polythérapie
EP3534885B1 (en) 2016-11-03 2021-01-20 Kura Oncology, Inc. Farnesyltransferase inhibitors for use in treating cancer
CN116987014A (zh) 2016-11-09 2023-11-03 诺沃梅迪科斯有限公司 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
US10106521B2 (en) 2016-11-09 2018-10-23 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
CN110191705A (zh) 2016-12-01 2019-08-30 亚尼塔公司 治疗癌症的方法
TW201827051A (zh) 2016-12-02 2018-08-01 美商神經性分泌生物科學公司 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
KR20190108146A (ko) 2017-01-27 2019-09-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CN114796218A (zh) 2017-02-21 2022-07-29 库拉肿瘤学公司 使用法尼基转移酶抑制剂治疗癌症的方法
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
WO2018175324A1 (en) 2017-03-20 2018-09-27 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
WO2018183781A1 (en) 2017-03-29 2018-10-04 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
JP2020515611A (ja) 2017-03-29 2020-05-28 サイトワン セラピューティクス， インコーポレイテッド 疼痛の処置のための１１，１３−修飾サキシトキシン
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
MX2019013562A (es) 2017-05-19 2020-08-03 Nflection Therapeutics Inc Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
CA3063536A1 (en) 2017-05-19 2018-11-22 Nflection Therapeutics, Inc. Pyrrolopyridine-aniline mek inhibitors for use in the treatment of dermal disorders
MX2019014272A (es) 2017-06-01 2020-12-11 Xoc Pharmaceuticals Inc Compuestos policiclicos y usos de los mismos.
JP2020528900A (ja) 2017-07-27 2020-10-01 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 体脂肪低減のためのプロスタサイクリン受容体アゴニスト
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
SG11202000894TA (en) 2017-08-07 2020-02-27 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors
US20200276209A1 (en) 2017-09-11 2020-09-03 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
WO2019060322A2 (en) 2017-09-21 2019-03-28 Neurocrine Biosciences, Inc. HIGH DOSAGE VALBENAZINE FORMULATION AND COMPOSITIONS, METHODS AND KITS THEREOF
WO2019074492A1 (en) 2017-10-10 2019-04-18 Obrien Christopher F METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CA3087856A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics, Llc Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
CN112638387A (zh) 2018-06-14 2021-04-09 纽罗克里生物科学有限公司 Vmat2抑制剂化合物、组合物和与其相关的方法
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
EP3836926A4 (en) 2018-08-15 2022-05-04 Neurocrine Biosciences, Inc. METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
EP3860714B1 (en) 2018-10-03 2023-09-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
SG11202104296TA (en) 2018-11-01 2021-05-28 Kura Oncology Inc Methods of treating cancer with farnesyltransferase inhibitors
JP7393808B2 (ja) 2018-11-20 2023-12-07 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのナフチリジノン－アニリン化合物
MA55148A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
EP3883552A4 (en) 2018-11-20 2022-08-17 NFlection Therapeutics, Inc. CYANOARYL ANILINE COMPOUNDS FOR THE TREATMENT OF SKIN DISEASES
CN113660931A (zh) 2018-11-20 2021-11-16 恩福莱克逊治疗有限公司 用于治疗皮肤癌的芳基苯胺和杂芳基苯胺化合物
US20230078755A1 (en) 2018-12-19 2023-03-16 Shy Therapeutics, Llc Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
WO2020132437A1 (en) 2018-12-21 2020-06-25 Kura Oncology, Inc. Therapies for squamous cell carcinomas
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
US11447468B2 (en) 2019-02-06 2022-09-20 Dice Alpha, Inc. IL-17 ligands and uses thereof
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
AU2020231396A1 (en) 2019-03-07 2021-10-21 Genome Opinion, Inc. Caspase inhibitors and methods of use thereof
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
CN113795253A (zh) 2019-03-29 2021-12-14 库拉肿瘤学公司 用法呢基转移酶抑制剂治疗鳞状细胞癌的方法
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CA3146157A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
CA3146159A1 (en) 2019-07-11 2021-01-14 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
WO2021021563A1 (en) 2019-07-26 2021-02-04 Espervita Therapeutics, Inc. Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
US20220288061A1 (en) 2019-09-02 2022-09-15 Camurus Ab Formulations and treatment methods
CN115103835A (zh) 2019-09-16 2022-09-23 戴斯阿尔法公司 Il-17a调节剂及其用途
WO2021059023A1 (en) 2019-09-26 2021-04-01 Abionyx Pharma Sa Compounds useful for treating liver diseases
TW202126631A (zh) 2019-10-01 2021-07-16 美商分子皮膚療法公司 作為klk5/7雙重抑制劑之苯并酮化合物
JP2021147329A (ja) * 2020-03-16 2021-09-27 株式会社リコー 粒子の製造方法
WO2021242970A1 (en) 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
KR20230051252A (ko) 2020-08-14 2023-04-17 사이트원 테라퓨틱스, 인코포레이티드 통증의 치료를 위한 nav 1.7의 비수화 케톤 억제제
EP4284377A1 (en) 2021-01-27 2023-12-06 Shy Therapeutics LLC Methods for the treatment of fibrotic disease
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
EP4304716A1 (en) 2021-03-10 2024-01-17 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
WO2023102378A1 (en) 2021-11-30 2023-06-08 Kura Oncology, Inc. Macrocyclic compounds having farnesyltransferase inhibitory activity
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
CN114404663A (zh) * 2022-01-07 2022-04-29 浙江瑞谷生物科技有限公司 一种具有炎症缓解特性的骨修复材料及其制备方法
CN114404664A (zh) * 2022-02-17 2022-04-29 浙江瑞谷生物科技有限公司 一种具备长效缓释的骨修复支架材料及其制备方法及应用
US20230303580A1 (en) 2022-03-28 2023-09-28 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
US20230348909A1 (en) 2022-03-30 2023-11-02 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
US20230331693A1 (en) 2022-04-14 2023-10-19 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the novel compounds
WO2023201348A1 (en) 2022-04-15 2023-10-19 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2023215781A1 (en) 2022-05-05 2023-11-09 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
WO2024054832A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
WO2024073473A1 (en) 2022-09-30 2024-04-04 Boulder Bioscience Llc Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
ATE61935T1 (de) * 1985-02-07 1991-04-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von mikrokapseln.
GB8609537D0 (en) * 1986-04-18 1986-05-21 Ici Plc Polyesters
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
JP2670680B2 (ja) 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
US5183662A (en) 1990-08-30 1993-02-02 Senju Pharmaceutical Co., Ltd. Controlled drug release composition
JP3277342B2 (ja) * 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
DK0669128T3 (da) 1992-11-17 2000-06-19 Yoshitomi Pharmaceutical Sustained-release mikrosfære indeholdende antipsykotikum og fremgangsmåde til at fremstille samme
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
DK0779806T3 (da) * 1994-09-09 2000-11-27 Takeda Chemical Industries Ltd Præparat til forsinket frigivelse indeholdende et metalsalt af et peptid
AU3533395A (en) 1994-09-30 1996-04-26 Takeda Chemical Industries Ltd. Oral sustained-release preparation

Also Published As

Publication number Publication date
DE69730093T2 (de) 2006-07-20
EP0839525A1 (en) 1998-05-06
ES2221019T3 (es) 2004-12-16
DK0839525T3 (da) 2004-11-29
CA2219698C (en) 2007-09-04
US6699500B2 (en) 2004-03-02
US20020031545A1 (en) 2002-03-14
JP4361144B2 (ja) 2009-11-11
JPH10182496A (ja) 1998-07-07
CA2219698A1 (en) 1998-04-30
EP0839525B1 (en) 2004-08-04
DE69730093D1 (de) 2004-09-09
US6113943A (en) 2000-09-05
ATE272394T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
PT839525E (pt) Preparacao de libertacao prolongada
CY1117889T1 (el) Πολυμερες γαλακτικου οξεος και διεργασια για την παραγωγη αυτου
PT809488E (pt) Preparacoes solidas de substancias activas****************
EP2258402A3 (en) Dried composition
OA09760A (fr) "Conjugués de protéine et de polyéthylène glycol".
NO995794D0 (no) Farmasöytisk preparat inneholdende "Lactobacillus casei rhamnosus"
MA25875A1 (fr) Nouveaux derives de l'acide aminodicarboxylique presentant des proprietes pharmaceutiques.
BR9507999A (pt) Conjugado biologicamente ativo composto substancialmente purificado polimero solúvel em água e composição farmacêutica
AU7992987A (en) Method and formulation for orally administering bioactive agents to and through the peyer's patch
SE8603582L (sv) Komposition innehallande l-dopa
DZ2199A1 (fr) Dihydrate d'éprosartan et son procédé de préparation et sa formulation.
NO913136D0 (no) Preparat for oeyedraaper.
FI970934A0 (fi) Implantoitava valukappale vaikuttavien aineiden annostelemiseksi kasveihin
NO942396L (no) Preparat med vedvarende frigiving av anti-endotelin substans
ITRM930291A0 (it) Procedimento per la preparazione di biopolimeri iodurati con attivita'disinfettante e cicatrizzante, e biopolimeri iodurati cosi' ottenuti.
AU6360790A (en) Stable immunogen composition for oral administration
DE69213183D1 (de) N'-Cyanomethylethylendiamin-N,N'-Diessigsäure, ihre Salze und ihre Herstellung
DE69521122T2 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
DE59000613D1 (de) Pflaster zur transdermalen anwendung.
NO880230D0 (no) Peroralt preparat med forsinket frigjoering.
ATE132877T1 (de) Emulgatorfreie emulsionspolymere in pharmazeutischen zubereitungen mit verzögerter wirkstofffreigabe und ihre herstellung
GB2341782A (en) Environmentally friendly chewing gum bases
FR2716460B1 (fr) Modèle animal de la maladie d'Alzheimer, préparation et utilisations.
DE69611546T2 (de) Herstellung von 2,6-dimethylnaphthalin
IT1282289B1 (it) 17-idrossiimminoalchil e 17-idrossiimminometilalchenil ciclopentaperidrofenantreni attivi sul sistema cardiovascolare,